Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting

References

• Chen H, Zhan Y, Zhang J, et al. The global, regional, and national burden and trends of NAFLD in 204 countries and territories: an analysis from global burden of disease 2019. JMIR Public Health Surveill. 2022;8(12):e34809. doi: 10.2196/34809
   PubMedGoogle Scholar
• Allen AM, Lazarus JV, Younossi ZM. Healthcare and socioeconomic costs of NAFLD: a global framework to navigate the uncertainties. J Hepatol. 2023;79(1):209–217. doi: 10.1016/j.jhep.2023.01.026
   PubMed Web of Science ®Google Scholar
• Lazarus JV, Mark HE, Anstee QM, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19:60–78. doi: 10.1038/s41575-021-00523-4
   PubMed Web of Science ®Google Scholar
• Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2024;29:101133. doi: 10.1016/j.aohep.2023.101133
   Web of Science ®Google Scholar
• Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28(5):528–562. doi: 10.1016/j.eprac.2022.03.010
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver (EASL). European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402. doi: 10.1016/j.jhep.2015.11.004
   PubMed Web of Science ®Google Scholar
• Calzadilla Bertot L, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci. 2016;17(5):774. doi: 10.3390/ijms17050774
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–1321. doi: 10.1002/hep.20701
   PubMed Web of Science ®Google Scholar
• Noureddin M, Vipani A, Bresee C, et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic gender variances. Am J Gastroenterol. 2018;113(11):1649–1659. doi: 10.1038/s41395-018-0088-6
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335–1347. doi: 10.1097/HEP.0000000000000004
   PubMed Web of Science ®Google Scholar
• Quek J, Chan KE, Wong ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20–30. doi: 10.1016/S2468-1253(22)00317-X
   PubMed Web of Science ®Google Scholar
• Harrison SA, Gawrieh S, Roberts K, et al. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol. 2021;75(2):284‒291. doi: 10.1016/j.jhep.2021.02.034
   Web of Science ®Google Scholar
• Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med. 2008;75(10):721–728. doi: 10.3949/ccjm.75.10.721
   PubMed Web of Science ®Google Scholar
• Long MT, Noureddin M, Lim JK. AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review. Gastroenterology. 2022;163(3):764–774.e1. doi: 10.1053/j.gastro.2022.06.023
   PubMed Web of Science ®Google Scholar
• Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123–133. doi: 10.1002/hep.29466
   PubMed Web of Science ®Google Scholar
• Rich NE, Noureddin M, Kanwal F, et al. Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA. Lancet Gastroenterol Hepatol. 2021;6(6):422–424. doi: 10.1016/S2468-1253(21)00100-X
   PubMed Web of Science ®Google Scholar
• Setiawan VW, Stram DO, Porcel J, et al. Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: the multiethnic cohort. Hepatology. 2016;64(6):1969–1977. doi: 10.1002/hep.28677
   PubMed Web of Science ®Google Scholar
• Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol. 2018;68(2):268–279. doi: 10.1016/j.jhep.2017.09.003
   PubMed Web of Science ®Google Scholar
• Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461–1465. doi: 10.1038/ng.257
   PubMed Web of Science ®Google Scholar
• Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2014;46:352–356. doi: 10.1038/ng.2901
   PubMed Web of Science ®Google Scholar
• Pirola CJ, Garaycoechea M, Flichman D, et al. Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease. J Lipid Res. 2019;60(1):176–185. doi: 10.1194/jlr.P089953
   PubMed Web of Science ®Google Scholar
• LaBrecque D, Abbas Z, Anania F, et al. World Gastroenterology Organisation global guidelines [Internet]. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. World Gastroenterology Organisation. 2012 [cited 2023 Aug 23]. Available from: https://www.worldgastroenterology.org/UserFiles/file/guidelines/nafld-nash-english-2012.pdf
   Google Scholar
• Cook N, Geier A, Schmid A, et al. The patient perspectives on future therapeutic options in NASH and patient needs. Front Med. 2019;6:61. doi: 10.3389/fmed.2019.00061
   PubMed Web of Science ®Google Scholar
• Alqahtani SA, Paik JM, Biswas R, et al. Poor awareness of liver disease among adults with NAFLD in the United States. Hepatol Commun. 2021;5(11):1833–1847. doi: 10.1002/hep4.1765
   PubMed Web of Science ®Google Scholar
• DeLegge MH. Recruitment and retention of patients for nonalcoholic steatohepatitis clinical trials. Gastroenterol Clin North Am. 2020;49(1):123–140. doi: 10.1016/j.gtc.2019.09.006
   PubMed Web of Science ®Google Scholar
• Kanwal F, Shubrook JH, Adams LA, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology. 2021;161(5):1657–1669. doi: 10.1053/j.gastro.2021.07.049
   PubMed Web of Science ®Google Scholar
• Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–1835. doi: 10.1097/HEP.0000000000000323
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J Hepatol. 2021;75(3):659–689. doi: 10.1016/j.jhep.2021.05.025
   PubMed Web of Science ®Google Scholar
• Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753‒2786. doi: 10.2337/dci22-0034
   Web of Science ®Google Scholar
• ElSayed NA, Aleppo G, Aroda VR, et al. American Diabetes Association Professional Practice Committee. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes—2024. Diabetes Care. 2024;47(Suppl. 1):S52–S76. doi: 10.2337/dc24-S004
   PubMedGoogle Scholar
• Song SJ, Lai JC, Wong GL, et al. Can we use old NAFLD data under the new MASLD definition? J Hepatol. 2024;80(2):e54–e56. doi: 10.1016/j.jhep.2023.07.021
   PubMed Web of Science ®Google Scholar
• Forlando R, Stanic T, Jayawardana S, et al. A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies. Liver Int. 2024;44(1):61–71. doi: 10.1111/liv.15730
   PubMed Web of Science ®Google Scholar
• Noureddin M, Jones C, Alkhouri N, et al. Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States is cost-effective: a comprehensive cost-utility analysis. Gastroenterology. 2020;159(5):1985–1987.e4. doi: 10.1053/j.gastro.2020.07.050
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357. doi:10.1002/hep.29367
   PubMed Web of Science ®Google Scholar
• Madrigal Pharmaceuticals [Internet]. Madrigal announces positive topline results from the pivotal phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. 2022 [cited 2023 Aug 23]. Avaialble from: https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-announces-positive-topline-results-pivotal-phase-3
   Google Scholar
• Noureddin M, Loomba R. Nonalcoholic fatty liver disease: indications for liver biopsy and noninvasive biomarkers. Clin Liver Dis. 2012;1(4):104–107. doi: 10.1002/cld.65
   Google Scholar
• Rich NE, Oji S, Mufti AR, et al. Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(2):198–210.e2. doi: 10.1016/j.cgh.2017.09.041
   PubMed Web of Science ®Google Scholar
• Dasarathy S, Dasarathy J, Khiyami A, et al. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol. 2009;51(6):1061–1067. doi: 10.1016/j.jhep.2009.09.001
   PubMed Web of Science ®Google Scholar
• Siddiqui MS, Yamada G, Vuppalanchi R, et al. Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage. Clin Gastroenterol Hepatol. 2019;17(9):1877–1885.e5. doi: 10.1016/j.cgh.2018.12.031
   PubMed Web of Science ®Google Scholar
• Unalp-Arida A, Ruhl CE. Liver fibrosis scores predict liver disease mortality in the United States population. Hepatology. 2017;66(1):84–95. doi: 10.1002/hep.29113
   PubMed Web of Science ®Google Scholar
• Lee J, Vali Y, Boursier J, et al. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review. Liver Int. 2021;41(2):261–270. doi: 10.1111/liv.14669
   PubMed Web of Science ®Google Scholar
• Doycheva I, Erickson D, Watt KD. Growth hormone deficiency and NAFLD: an overlooked and underrecognized link. Hepatol Commun. 2022;6(9):2227–2237. doi: 10.1002/hep4.1953
   PubMed Web of Science ®Google Scholar
• McPherson S, Hardy T, Dufour J-F, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112(5):740–751. doi: 10.1038/ajg.2016.453
   PubMed Web of Science ®Google Scholar
• Dufour J-F, Antsee QM, Bugianesi E, et al. Current therapies and new developments in NASH. Gut. 2022;71(10):2123–2134. doi: 10.1136/gutjnl-2021-326874
   PubMed Web of Science ®Google Scholar
• Srivastava A, Jong S, Gola A, et al. Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease. BMC Gastroenterol. 2019;19:122. doi: 10.1186/s12876-019-1039-4
   PubMed Web of Science ®Google Scholar
• Kang MK, Kim MC. Clinical implications of cardiac symptoms and electrocardiographic abnormalities for advanced liver fibrosis in patients with nonalcoholic fatty liver disease. Medicina (Kaunas). 2023;59(2):375. doi: 10.3390/medicina59020375
   PubMed Web of Science ®Google Scholar
• Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51(1):121‒129. doi: 10.1002/hep.23276
   PubMed Web of Science ®Google Scholar
• Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367–378. doi: 10.1053/j.gastro.2015.04.005
   PubMed Web of Science ®Google Scholar
• Chan W-K, Chuah K-H, Rajaram B, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. J Obes Metab Syndr. 2023;32(3):197–213. doi: 10.7570/jomes23052
   PubMed Web of Science ®Google Scholar
• Kim HK, Bae SJ, Lee MJ, et al. Association of visceral fat obesity, sarcopenia, and myosteatosis with non-alcoholic fatty liver disease without obesity. Clin Mol Hepatol. 2023;29(4):987–1001. doi: 10.3350/cmh.2023.0035
   PubMed Web of Science ®Google Scholar
• Sinn DH, Kang D, Kang M, et al. Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: a longitudinal cohort study. Hepatology. 2022;76(6):1746–1754. doi: 10.1002/hep.32578
   PubMed Web of Science ®Google Scholar
• Koo BK, Kim D, Joo SK, et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol. 2017;66(1):123–131. doi: 10.1016/j.jhep.2016.08.019
   PubMed Web of Science ®Google Scholar
• Du J, Ma S, Fang L, et al. Association between regional body muscle mass and non-alcoholic fatty liver disease: an observational study using data from the REACTION study. J Pers Med. 2023;13(2):209. doi: 10.3390/jpm13020209
   PubMed Web of Science ®Google Scholar
• Master H, Annis J, Huang S, et al. Association of step counts over time with the risk of chronic disease in the All of Us Research Program. Nat Med. 2022;28:2301‒2308. doi: 10.1038/s41591-022-02012-w
   PubMed Web of Science ®Google Scholar
• Wadden TA, Tronieri JS, Butryn ML. Lifestyle modification approaches for the treatment of obesity in adults. Am Psychol. 2020;75(2):235–251. doi: 10.1037/amp0000517
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Brunt EM, Kleiner DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology. 2011;54(1):344–353. doi: 10.1002/hep.24376
   PubMedGoogle Scholar
• Åberg F, Puukka P, Salomaa V, et al. Risks of light and moderate alcohol use in fatty liver disease: follow-up of population cohorts. Hepatology. 2020;71(3):835–848. doi: 10.1002/hep.30864
   PubMed Web of Science ®Google Scholar
• Mantovani A, Petracca G, Beatrice G, et al. Glucagon‐like peptide‐1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta‐analysis of randomized controlled trials. Metabolites. 2021;11(2):73. doi: 10.3390/metabo11020073
   PubMed Web of Science ®Google Scholar
• Barritt AS 4th, Marshman E, Noureddin M. Review article: role of glucagon‐like peptide‐1 receptor agonists in non‐alcoholic steatohepatitis, obesity and diabetes—what hepatologists need to know. Aliment Pharmacol Ther. 2022;55(8):944–959. doi: 10.1111/apt.16794
   PubMed Web of Science ®Google Scholar
• Shao N, Kuang HY, Hao M, et al. Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes. Diabetes Metab Res Rev. 2014;30(6):521–529. doi: 10.1002/dmrr.2561
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–690. doi: 10.1016/S0140-6736(15)00803-X
   PubMed Web of Science ®Google Scholar
• Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384:1113–1124. doi: 10.1056/NEJMoa2028395
   PubMed Web of Science ®Google Scholar
• Loomba R, Abdelmalek MF, Armstrong M, et al. Semaglutide 2.4 mg once weekly improved liver and metabolic parameters, and was well tolerated, in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial [oral presentation]. J Hepatol. 2022;77(Suppl 1):S10.LB001. doi: 10.1016/S0168-8278(22)00440-8
   Google Scholar
• Cusi K. Time to include nonalcoholic steatohepatitis in the management of patients with type 2 diabetes. Diabetes Care. 2020;43(2):275–279. doi: 10.2337/dci19-0064
   PubMed Web of Science ®Google Scholar
• Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. JHEP Rep. 2019;1(4):312–328. doi: 10.1016/j.jhepr.2019.07.002
   PubMedGoogle Scholar
• Pradhan R, Yin H, Yu O, et al. Glucagon-like peptide 1 receptor agonists and sodium–glucose cotransporter 2 inhibitors and risk of nonalcoholic fatty liver disease among patients with type 2 diabetes. Diabetes Care. 2022;45(4):819–829. doi: 10.2337/dc21-1953
   PubMed Web of Science ®Google Scholar
• Genua I, Cusi K. Pharmacological approaches to NAFLD: current and future therapies. Diabetes Spectr. 2024;37(1):48–58. Epub ahead of print. doi: 10.2337/dsi23-0012
   PubMedGoogle Scholar
• Cusi K, Bril F, Barb D, et al. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diab Obes Metab. 2019;21(4):812–821. doi: 10.1111/dom.13584
   PubMed Web of Science ®Google Scholar
• Gastaldelli A, Cusi K, Landó LF, et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10(6):393–406. doi: 10.1016/S2213-8587(22)00070-5
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184–2196. doi: 10.1016/S0140-6736(19)33041-7
   PubMed Web of Science ®Google Scholar
• GlobalNewswire [Internet]. Intercept receives complete response letter from FDA for obeticholic acid as a treatment for pre-cirrhotic fibrosis due to NASH. 2023 [cited 2023 Aug 23]. Available from: https://www.globenewswire.com/news-release/2023/06/22/2693358/0/en/Intercept-Receives-Complete-Response-Letter-from-FDA-for-Obeticholic-Acid-as-a-Treatment-for-Pre-Cirrhotic-Fibrosis-due-to-NASH.html
   Google Scholar
• Esteban JPG, Asgharpour A. Evaluation of liver transplant candidates with non-alcoholic steatohepatitis. Transl Gastroenterol Hepatol. 2022;7:24. doi: 10.21037/tgh.2020.03.04
   PubMed Web of Science ®Google Scholar
• Thapar M, Russo MW, Bonkovsky HL. Statins and liver injury. Gastroenterol Hepatol. 2013;9(9):605–606.
   PubMedGoogle Scholar
• Lazure P, Tomlinson JW, Kowdley KV, et al. Clinical practice gaps and challenges in non-alcoholic steatohepatitis care: an international physician needs assessment. Liver Int. 2022;42(8):1772‒1782. doi: 10.1111/liv.15324
   PubMed Web of Science ®Google Scholar
• von dem Knesebeck O, Koens S, Marx G, et al. Perceptions of time constraints among primary care physicians in Germany. BMC Fam Pract. 2019;20:142. doi: 10.1186/s12875-019-1033-5
   PubMed Web of Science ®Google Scholar
• Linzer M, Konrad TR, Douglas J, et al. Managed care, time pressure, and physician job satisfaction: results from the physician worklife study. J Gen Intern Med. 2000;15(7):441–450. doi: 10.1046/j.1525-1497.2000.05239.x
   PubMed Web of Science ®Google Scholar
• Roser P, Bajaj SS, Stanford FC. International lack of equity in modern obesity therapy: the critical need for change in health policy. Int J Obes. 2022;46:1571–1572. doi: 10.1038/s41366-022-01176-2
   PubMed Web of Science ®Google Scholar
• Gu Y, Zhou R, Kong T, et al. Barriers and enabling factors in weight management of patients with nonalcoholic fatty liver disease: a qualitative study using the COM-B model of behaviour. Health Expect. 2023;26(1):355‒365. doi: 10.1111/hex.13665
   PubMed Web of Science ®Google Scholar
• Do A, Kuszewski EJ, Langberg KA, et al. Incorporating weight loss medications into hepatology practice for nonalcoholic steatohepatitis. Hepatology. 2019;70(4):1443‒1456. doi: 10.1002/hep.30658
   PubMed Web of Science ®Google Scholar
• Lazarus JV, Kakalou C, Palayew A, et al. A Twitter discourse analysis of negative feelings and stigma related to NAFLD, NASH and obesity. Liver Int. 2021;41(10):2295‒2307. doi: 10.1111/liv.14969
   Web of Science ®Google Scholar
• Carol M, Pérez-Guasch M, Solà E, et al. Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life. PLoS One. 2022;17(4):e0265153. doi: 10.1371/journal.pone.0265153
   PubMed Web of Science ®Google Scholar
• Said A, Gagovic V, Malecki K, et al. Primary care practitioners survey of non-alcoholic fatty liver disease. Ann Hepatol. 2013;12(5):758‒765. doi: 10.1016/S1665-2681(19)31317-1
   PubMed Web of Science ®Google Scholar
• Ratziu V, Cadranel J-F, Serfaty L, et al. A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in France. J Hepatol. 2012;57(2):376‒383. doi: 10.1016/j.jhep.2012.03.019
   Web of Science ®Google Scholar
• Ayada I, van Kleef LA, Zhang H, et al. Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study. EBioMedicine. 2023;87:104392. doi: 10.1016/j.ebiom.2022.104392
   PubMed Web of Science ®Google Scholar
• Kothari S, Dhami-Shah H, Shah SR. Antidiabetic drugs and statins in nonalcoholic fatty liver disease. J Clin Exp Hepatol. 2019;9(6):723–730. doi: 10.1016/j.jceh.2019.06.003
   PubMed Web of Science ®Google Scholar